Six consecutive years! Medicilon once again tops the '2023 China CXO Enterprise Top 20 List'

On June 25^th, the "Resilience and Innovation: 2024 Mithink Summit" hosted by Menet, a subsidiary of the Southern Institute of Medical Economics under the National Medical Products Administration, released the 2023 China Pharmaceutical Industry Top 100 Rankings lists.  Medicilon, with its outstanding R&D capabilities and continuous spirit of innovation, has once again topped the 2023 China CXO (including CDMO) Enterprise Top 20 List.  This is the sixth consecutive year that Medicilon has received this honor.

Medicilon's sixth consecutive win of this honor not only represents the industry's authoritative recognition of its comprehensive biopharmaceutical preclinical R&D service platform, but also affirms its contributions to the pharmaceutical research and development field.

About the China's Top 100 Pharmaceutical Industry List Series

The "China's Top 100 Pharmaceutical Industry List Series" as an authoritative industry list, initiated and hosted by Menet.com.cn, aims to set benchmarks for china pharmaceutical enterprises to enhance comprehensive strength, expand brand influence, showcase outstanding achievements in the pharmaceutical industry, and guide stable, rapid, and sustainable development in the healthcare industry.  Menet Research Institute, leveraging its exclusively developed and operated database covering three major terminals and six market segments, conducted a rigorous and scientific selection process based on two crucial dimensions for pharmaceutical industry enterprises: innovation driving force and professional promotion capability. This process ultimately determined the China's Top 100 Pharmaceutical Industry List Series.

With the rapid development of pharmaceutical technology, emerging fields such as bispecific/multispecific antibodies, ADCs, PROTACs, mRNA vaccines, small nucleic acids, and cellular and immune therapies are gradually becoming the focus of industry attention.  Medicilon actively plans forward, establishing a series of efficient and cutting-edge technology service platforms, continuously driving technological innovation and iteration, and leading industry development trends.  As of the end of April 2024, Medicilon has provided drug development services to over 2,000 global clients. They have been involved in the research and development of 480 new drug and generic drug projects, with IND approvals obtained from regulatory authorities such as China NMPA, the US FDA, the EU EMEA, and Australia TGA, allowing entry into clinical trials.